Archive for the 'pharmacy benefit managers' Category

Pharmacy Closures With A Twist

By John Norton

The National Community Pharmacists Association (NCPA) tracks newspaper articles about independent community pharmacy closings to follow why such pharmacies close. The reasons are often related to the challenges community pharmacies face often due to predatory business tactics of largely unregulated pharmacy benefit managers (PBMs). Currently topping the lists of reasons are PBM reimbursements for generic prescription drugs that fail to keep up with spiking acquisition costs and exclusionary Medicare Part D “preferred pharmacy” plans.

Continue reading ‘Pharmacy Closures With A Twist’

That Man Behind the Curtain? Pay No Attention

By Kevin Schweers

Confusion and complexity are arguably critical to how pharmacy benefit managers (PBMs) are so profitable. Perhaps it should come as no surprise that those methods are also integral to their most recent efforts to thwart pro-patient, pro-pharmacist policies.

Continue reading ‘That Man Behind the Curtain? Pay No Attention’

Senators back more MTM in Medicare drug plans

By Kevin Schweers

A bipartisan report from the Senate Aging Committee focuses on how to increase utilization of generic drugs to lower costs and specifically suggests expanded eligibility for medication therapy management (MTM) services, such as from community pharmacists. Continue reading ‘Senators back more MTM in Medicare drug plans’

The “Lock-In” Pharmacy Approach to Rx Drug Abuse

By Kevin Schweers

A proposal to restrict certain Medicare beneficiaries to use only a dedicated, “lock-in” pharmacy for their controlled substances is now a part of legislation introduced by two House lawmakers. Continue reading ‘The “Lock-In” Pharmacy Approach to Rx Drug Abuse’

Members of Congress Scrutinize Sky-rocketing Costs of Generic Drugs

By Michael Rule

Last January, NCPA urged Congress to investigate soaring generic drug prices after a member survey found that acquisition costs for some drugs had increased by more than 1,000%, but that reimbursement to pharmacies did not keep up. This call was recently answered by Sen. Bernie Sanders (I-Vt.) and Rep. Elijah E. Cummings (D-Md.) who launched an inquiry.

Continue reading ‘Members of Congress Scrutinize Sky-rocketing Costs of Generic Drugs’

Payers Call for Greater PBM Transparency

By Michael Rule

For years, NCPA has been at the forefront in calling for greater transparency in the operations of pharmacy benefit managers (PBMs), from highlighting difficulties plan sponsors often have in auditing their PBM to noting PBM practices that may increase costs to plans while increasing profits for the PBMs. While the PBMs claim there is already adequate transparency, their policies are drawing increased scrutiny.

Continue reading ‘Payers Call for Greater PBM Transparency’

The Morning After

By Kurt A. Proctor, Ph.D., RPh, NCPA Senior Vice President, Strategic Initiatives

After a great NCPA Annual Meeting in Austin, we weren’t done. On Wednesday, October 22nd we kept the momentum going with a day-long “Networking for High Performance Pharmacies” program for a standing room only crowd of 140 industry leaders. This provocative program afforded like-minded pharmacists not only the opportunity to get to know each other but to engage with public and private payers to hear about their plans for pay-for-performance and quality related network inclusion criteria.

Continue reading ‘The Morning After’


Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Search by Categories


Follow

Get every new post delivered to your Inbox.

Join 503 other followers